RAPT Therapeutics/$RAPT
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Ticker
$RAPT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
67
ISIN
US75382E2081
Website
RAPT Metrics
BasicAdvanced
$132M
-
-$10.97
-0.14
-
Price and volume
Market cap
$132M
Beta
-0.14
52-week high
$9.84
52-week low
$6.88
Financial strength
Current ratio
21.11
Quick ratio
20.659
Long term debt to equity
0.857
Total debt to equity
2.162
Profitability
EBITDA (TTM)
-121.707
Management effectiveness
Return on assets (TTM)
-44.72%
Return on equity (TTM)
-75.60%
Valuation
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-0.782
Free cash flow yield (TTM)
-127.93%
Free cash flow per share (TTM)
-1,023.45%
Growth
Earnings per share change (TTM)
-55.36%
3-year earnings per share growth (CAGR)
-18.79%
RAPT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RAPT Therapeutics stock?
RAPT Therapeutics (RAPT) has a market cap of $132M as of July 01, 2025.
What is the P/E ratio for RAPT Therapeutics stock?
The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of July 01, 2025.
Does RAPT Therapeutics stock pay dividends?
No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next RAPT Therapeutics dividend payment date?
RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.
What is the beta indicator for RAPT Therapeutics?
RAPT Therapeutics (RAPT) has a beta rating of -0.14. This means that it has an inverse relation to market volatility.